KCT0005442进行中（未招募）未知
Treatment of CNS germinoma using chemotherapy followed by reduced dose radiotherapy
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 3(Year) 至 30(Year)（—）
- 性别
- All
入选标准
- •1) Pathologically proven CNS germinoma
- •2) Age: 3-30 years
- •3) Normal plasma and CSF aFP
- •4) Plasma and CSF b-hCG < 200 mIU/ml
- •5) Patients with informed consent
排除标准
- •1) Patients with organ dysfunction as follows
- •- Serum Cr > 1.5 x ULN or creatinine clearance = 30 mL/min
- •- Cardiac ejection fraction <40% or severe arrhythmia or conduction disorder
- •2) Other sever mediacal illness which makes scheduled treatment impossible
- •3) Pregnant or nursing women
- •4) Patients with a past history of severe hypersensitivity to clinical trial drugs
- •5) Patients who are currently using pentostatin
研究者
相似试验
Unknown
2 期
Chemotherapy Plus Reduced Radiotherapy in Intracranial GerminomaIntracranial GerminomaNCT02782754Samsung Medical Center40
招募中
2 期
Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma2024-519046-79-00Oulu University Hospital100
进行中（未招募）
1 期
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaMedDRA version: 8.1Level: PTClassification code 10007953Term: Central nervous system lymphomaEUCTR2006-004772-12-DKordic Lymphoma Group70
招募中
1 期
eoantigen based chemoimmunotherapyadvanced pancreatic cancerpancreatic cancer, neoantigen, dendritic cell, cancer vaccinesJPRN-jRCTc030190081Koido Shigeo10
进行中（未招募）
1 期
WT1 based chemoimmunotherapyJPRN-jRCTc030190195Koido Shigeo10